However, a partial argument against this hypothesis is that the GFR-lowering effect of SGLT2 inhibitors also occurred in clinical trials with non-diabetic CKD patients receiving RAS blockers (Cherney et al., 2020; Heerspink et al., 2020). The gene discussed is SLC5A2; the disease is chronic kidney disease.